ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision ScienceBusiness Wire • 03/19/25
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025Business Wire • 03/13/25
ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025Business Wire • 02/25/25
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025Business Wire • 01/06/25
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to GrowZacks Investment Research • 12/24/24
ChromaDex (CDXC) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 12/09/24
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products CategoryBusiness Wire • 12/03/24
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 11/22/24
Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's WhyZacks Investment Research • 11/21/24
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity SupplementBusiness Wire • 11/14/24
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics NationwideBusiness Wire • 11/07/24
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 11/05/24
ChromaDex (CDXC) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 11/05/24
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024Business Wire • 10/28/24